Medivation, Inc. To Present Additional Alzheimer's Disease Data At Biotechnology Industry Organization (BIO) Investor Forum 2006

SAN FRANCISCO, Oct. 16 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that it will present additional data from the recently completed Alzheimer's disease clinical trial of the Company's investigational drug Dimebon(TM) at the BIO Investor Forum 2006. David Hung, M.D., president and chief executive officer of Medivation, will present on Thursday, October 19, at 9:40 a.m. Pacific Time at the Palace Hotel in San Francisco. A live audio webcast of the presentation will be available on the Company's website at www.medivation.com, and a replay will also be available for 30 days following the live presentation.

Medivation disclosed last month that Dimebon met all five efficacy endpoints in a six-month randomized, double-blinded, placebo-controlled trial of 183 patients with mild to moderate Alzheimer's disease. Patients in the trial were tested for a full spectrum of problems typically caused by Alzheimer's disease, including memory loss, behavioral disturbances, and inability to perform everyday activities such as bathing and dressing. After six months of treatment, patients on Dimebon got significantly better on all of these tests. Dimebon patients also scored significantly better on all of these tests than did placebo patients.

About Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase, and develops them quickly and cost-effectively through human first proof-of-efficacy studies. Depending on the indication, Medivation will either seek to sell or partner successful programs with larger companies for late-stage clinical studies and commercialization, or alternatively conduct those activities independently. Medivation's current portfolio consists of small molecule drugs in development to treat 3 large, unmet medical needs - Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of 4 to 6 development programs at all times. For more information, please go to www.medivation.com.

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates have been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2005, and its Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2006 and June 30, 2006, include more information about factors that could affect the Company's financial and operating results.

CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,+1-415-543-3470, or ext. 201; or Jani Bergan of WeissComm Partners,+1-415-946-1064

Web site: http://www.medivation.com//